$6.79+0.07 (+1.04%)
LENZ Therapeutics, Inc.
LENZ Therapeutics, Inc. in the Healthcare sector is trading at $6.79. Wall Street consensus targets $32.00, implying a +371.3% move over the next 12 months. The stock is currently near its 52-week low of $6.52, remaining 67.9% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of pre...
LENZ Therapeutics, Inc. (NASDAQ:LENZ) said Everest Medicines has acquired the rights to develop and commercialize VIZZ, also known as LNZ100, in Greater China. Under the agreement, Everest Medicines (HKEX:1952) takes on development and commercialization of the drug in the Greater China...
The analysts covering LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) delivered a dose of negativity to shareholders today, by...
It's been a sad week for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ), who've watched their investment drop 17% to US$8.05...
Power Solutions International (PSIX) reported late Monday lower-than-expected adjusted EPS and reven
Toast downgraded, Lowe's upgraded: Wall Street's top analyst calls